Table 3 Response to therapy of patients with grade 1, 2 and 3A
N | Total | Mutated EZH2 in FFPE (n = 36) | Unmutated EZH2 in FFPE (n = 105) | p-valor | |
|---|---|---|---|---|---|
(n = 141) | |||||
Outcome, n (%) | |||||
First-line therapy, n (%) | 141 | ||||
Treated | 123 (87) | 30 (83) | 93 (89) | 0.4 | |
Watchful waiting | 18 (13) | 6 (17) | 12 (11) | ||
Progression | 4 (3) | 1 (2.8) | 3 (2.9) | 0.7 | |
Transformation | 4 (3) | 1 (2.8) | 3 (2.9) | 0.7 | |
POD24 | 13 (9.2) | 4 (11.1) | 9 (8.6) | 0.4 | |
Relapse | 25 (17.8) | 4 (11) | 21 (20) | 0.1 | |
Death | 22 (15.6) | 2 (5.5) | 20 (19) | 0.034 | |
R-Bendamustine | 30 | 30 (24) | 7 (23) | 23 (25) | |
Complete remission | 29 (97) | 7 | 22 (96) | 0.8 | |
Partial remission | 0 | 0 | 0 | NA | |
Progression | 1 (3.5) | 0 | 1 (4.4) | NA | |
Transformation | 0 | 0 | 0 | NA | |
POD24 | 4 (13.3) | 2 (29) | 2 (9) | 0.2 | |
Relapse | 4 (13.3) | 2 (5.6) | 2 (1.9) | 0.2 | |
Death | 4 (13.3) | 1 (14.2) | 3 (13) | 0.7 | |
R-CHOP | 67 | 67 (55) | 18 (60) | 49 (52) | |
Complete remission | 62 (93) | 16 (89) | 48 (98) | 0.8 | |
Partial remission | 1 (1.5) | 0 | 1 (2) | NA | |
Not assesseda | 2 (3) | 2 (11) | 0 | NA | |
Progression | 0 | 0 | 0 | NA | |
Transformation | 0 | 0 | 0 | NA | |
POD24 | 6 (9) | 1 (5.5) | 5 (10) | 0.4 | |
Relapse | 18 | 2 (11) | 16 (32) | 0.052 | |
Death | 11 (16.5) | 1 (2.8) | 10 (9.5) | 0.13 | |
R-CVP, Rituximab and Radiotherapy | 26 | 26 (21) | 5 (17) | 21 (23) | |